About 3-hydroxyanthranilate 3,4-dioxygenase
3-hydroxyanthranilate 3,4-dioxygenase (HAAO) is a protein
from Homo sapiens identified by UniProt accession
P46952, 286 residues long.
MolForge cross-references it against 0 known binders and
163 disease associations.
Target properties
| Protein name | 3-hydroxyanthranilate 3,4-dioxygenase |
|---|
| UniProt accession | P46952 |
|---|
| Gene | HAAO |
|---|
| Organism | Homo sapiens |
|---|
| Length | 286 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (163)
Diseases linked to this target (Open Targets).
- vertebral, cardiac, renal, and limb defects syndrome 1 · score 0.71
- congenital vertebral-cardiac-renal anomalies syndrome · score 0.60
- systolic blood pressure · score 0.43
- diastolic blood pressure · score 0.43
- mean corpuscular volume · score 0.42
- smoking status measurement · score 0.39
- white matter hyperintensity measurement · score 0.36
- protein measurement · score 0.34
- refractive error measurement · score 0.33
- platelet count · score 0.32
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P46952-F1 | alphafold | PREDICTED | 95.83 | — |
Amino-acid sequence (286 residues)
MERRLGVRAW VKENRGSFQP PVCNKLMHQE QLKVMFIGGP NTRKDYHIEE GEEVFYQLEG DMVLRVLEQG KHRDVVIRQG EIFLLPARVP HSPQRFANTV GLVVERRRLE TELDGLRYYV GDTMDVLFEK WFYCKDLGTQ LAPIIQEFFS SEQYRTGKPI PDQLLKEPPF PLSTRSIMEP MSLDAWLDSH HRELQAGTPL SLFGDTYETQ VIAYGQGSSE GLRQNVDVWL WQLEGSSVVT MGGRRLSLAP DDSLLVLAGT SYAWERTQGS VALSVTQDPA CKKPLG
Explore 3-hydroxyanthranilate 3,4-dioxygenase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets